Xcout Intel
Allena Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Allena Pharmaceuticals among biopharmaceuticals companies — ranked by similarity to what Allena Pharmaceuticals actually does, not by market-cap band.
Subscribe to see Allena Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Allena Pharmaceuticals at a glance
Allena Pharmaceuticals is a biopharmaceuticals company headquartered in United States. It has raised at least $70.5M across the 3 funding rounds on record. Its most recent funding round raised $4.1M in May 2022. Xcout tracks 3 named people at Allena Pharmaceuticals, including Bob Goodman (Firm Management).
Allena Pharmaceuticals leadership
- Bob GoodmanFirm Management
- Scott RingFirm Management
- Ibrahim FaruqiVice President
Allena Pharmaceuticals funding rounds
At least $70.5M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $4.1M | — | |
| SEC Form D filing | $51.4M | — | |
| Series A | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Allena Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Allena Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biopharmaceuticals company
Alnara Pharmaceuticals is a privately held biotechnology company based in Cambridge, Massachusetts, focused on developing novel protein therapeutics for the treatment of metabolic diseases. Its product pipeline includes liprotamase. The company was acquired by Eli Lilly and Company.
Similar biopharmaceuticals company
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, dedicated to advancing therapies to treat rare diseases.
Drug Discovery
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Drug Discovery
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Drug Discovery
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Similar biopharmaceuticals company
Mendra is a venture-backed biotechnology research startup established in 2025 and headquartered in San Francisco, focused on accelerating the development and commercialization of rare disease therapies.
Similar biopharmaceuticals company
Cydan is a biotechnology company builder and accelerator focused on creating and financing companies that develop treatments for rare diseases. It works with researchers, entrepreneurs, and investors to advance therapeutic programs toward clinical development.
Drug Discovery
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Drug Discovery
Courage Therapeutics, Inc. is a for-profit biotechnology company founded in 2019 and headquartered in Newton, Massachusetts. The company operates in the biotech sector with a focus on developing therapeutic solutions.
Similar biopharmaceuticals company
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Biopharma
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Drug Discovery
AIRNA Corp is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing RNA editing therapeutics. Its leading program utilizes ADAR-recruiting technology to target specific RNA locations for therapeutic applications.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Allena Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Allena Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →